Enarodustat
As of the edition of 20 October 2026, Enarodustat is a small molecule: marketed, first approved in 2020 (JP); acts on EGLN1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Enaroy
- First approved
- 25 September 2020 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Japan Tabacco; 2 holders in all
- Registered trials
- 10, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGLN1 | Egl nine homolog 1 | Q9GZT9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 3 | 3 | 1 | 1 | 1 |
| Phase 4 | 2 | 0 | 2 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Japan Tobacco | Applicant | 2020 to now |